Cargando…

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports

Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study we...

Descripción completa

Detalles Bibliográficos
Autores principales: Salem, M., Reichlin, T., Fasel, D., Leuppi-Taegtmeyer, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Magdi Yacoub Heart Foundation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871400/
https://www.ncbi.nlm.nih.gov/pubmed/29644223
http://dx.doi.org/10.21542/gcsp.2017.11
_version_ 1783309642430939136
author Salem, M.
Reichlin, T.
Fasel, D.
Leuppi-Taegtmeyer, A.
author_facet Salem, M.
Reichlin, T.
Fasel, D.
Leuppi-Taegtmeyer, A.
author_sort Salem, M.
collection PubMed
description Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study were therefore to identify all cases of torsade de pointes associated with systemic azole antifungal use reported to the WHO monitoring centre (Uppsala, Sweden) and to determine the latency times between commencing the azole and developing torsade de pointes. Methods: Investigator-driven, retrospective, descriptive analysis of post-marketing pharmacovigilance data regarding systemic azole antifungal agents and the development of torsade de pointes reported to the WHO monitoring centre 1995–2015. Results: 191 cases were reported as follows: fluconazole 130, itraconazole 22, ketoconazole 5, posaconazole 1, voriconazole 33. More than half of all cases involved concomitant suspected or interacting drugs. The median latency times between starting the azole and developing torsade de pointes ranged from 1 (posaconazole) – 9.5 days (itraconazole), range <1–250). Conclusions: Clinicians should be aware of these features of azole-associated torsade de pointes, avoid interacting drugs if at all possible and monitor at-risk patients.
format Online
Article
Text
id pubmed-5871400
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Magdi Yacoub Heart Foundation
record_format MEDLINE/PubMed
spelling pubmed-58714002018-04-11 Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports Salem, M. Reichlin, T. Fasel, D. Leuppi-Taegtmeyer, A. Glob Cardiol Sci Pract Pharmacovigilance Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study were therefore to identify all cases of torsade de pointes associated with systemic azole antifungal use reported to the WHO monitoring centre (Uppsala, Sweden) and to determine the latency times between commencing the azole and developing torsade de pointes. Methods: Investigator-driven, retrospective, descriptive analysis of post-marketing pharmacovigilance data regarding systemic azole antifungal agents and the development of torsade de pointes reported to the WHO monitoring centre 1995–2015. Results: 191 cases were reported as follows: fluconazole 130, itraconazole 22, ketoconazole 5, posaconazole 1, voriconazole 33. More than half of all cases involved concomitant suspected or interacting drugs. The median latency times between starting the azole and developing torsade de pointes ranged from 1 (posaconazole) – 9.5 days (itraconazole), range <1–250). Conclusions: Clinicians should be aware of these features of azole-associated torsade de pointes, avoid interacting drugs if at all possible and monitor at-risk patients. Magdi Yacoub Heart Foundation 2017-06-30 /pmc/articles/PMC5871400/ /pubmed/29644223 http://dx.doi.org/10.21542/gcsp.2017.11 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pharmacovigilance
Salem, M.
Reichlin, T.
Fasel, D.
Leuppi-Taegtmeyer, A.
Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
title Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
title_full Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
title_fullStr Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
title_full_unstemmed Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
title_short Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
title_sort torsade de pointes and systemic azole antifungal agents: analysis of global spontaneous safety reports
topic Pharmacovigilance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871400/
https://www.ncbi.nlm.nih.gov/pubmed/29644223
http://dx.doi.org/10.21542/gcsp.2017.11
work_keys_str_mv AT salemm torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports
AT reichlint torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports
AT faseld torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports
AT leuppitaegtmeyera torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports